Francesca Bonanni
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Francesca Bonanni has a total of 81 co-authors. Here are the top co-authors by number of shared publications:
- Iacopo Olivotto
University of Florence
5 shared publications Adalgisa Cordisco
Division of Prenatal Diagnosis, Azienda USL Toscana Centro, San Giovanni di Dio Hospital, Florence, Italy
3 shared publicationsGiovanni Battista Calabri
Cardiology Unit, Meyer Children's Hospital IRCCS, Florence, Italy
3 shared publicationsIacopo Olivotto
Cardiology Unit, Meyer Children's Hospital IRCCS, Florence, Italy; Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy
3 shared publicationsSilvia Favilli
Cardiology Unit, Meyer Children's Hospital IRCCS, Florence, Italy
3 shared publicationsAlberto Giannoni
Health Science Interdisciplinary Center, Sant’Anna School of Advanced Studies, Pisa, Italy
2 shared publications
Latest Publications
- 1 October 2026
- Published by Wolters Kluwer Health in Circulation: Genomic and Precision Medicine
- Vol. 19 (5) , e005725
Influence of Genotype on Cardiac Phenotype in Pediatric Hypertrophic Cardiomyopathy
- 1 October 2026
- Published by Wolters Kluwer Health in Circulation: Genomic and Precision Medicine
- Vol. 19 (5) , e005725
Influence of Genotype on Cardiac Phenotype in Pediatric Hypertrophic Cardiomyopathy
Cardiac mechanopathies: regional stress maldistribution as a primary determinant of myocardial disease
The heart relies on finely tuned spatial heterogeneity in wall structure, fibre orientation, blood distribution and excitation–contraction coupling to maintain mechanical homeostasis. Even minor deviations may interact with anisotropy to promote maladaptation and disease. While cardiomyopathies have classically been attributed to primary cellular defects, emerging evidence suggests that abnormal regional stress may act as a primary driver of pathology even in the absence of intrinsic sarcomeric dysfunction. This review proposes the concept of ‘cardiac mechanopathies’, conditions in which misdirected or disproportionate mechanical forces are hypothesised to act as primary determinants of maladaptive remodelling, culminating in a cardiomyopathic phenotype. Clinical paradigms include arrhythmogenic mitral valve prolapse and apical hypertrophic cardiomyopathy with papillary muscle displacement. While a direct causality link still needs to be established, this concept is conceived as a working hypothesis for future studies. Advanced imaging may help identify subtle structural abnormalities early, while insights into the molecular basis of maladaptation may reveal new therapeutic targets. Clinically, studies are needed to understand whether reducing mechanical stress through interventions and lifestyle modifications can mitigate disease expression and progression.
Cardiac mechanopathies: regional stress maldistribution as a primary determinant of myocardial disease
The heart relies on finely tuned spatial heterogeneity in wall structure, fibre orientation, blood distribution and excitation–contraction coupling to maintain mechanical homeostasis. Even minor deviations may interact with anisotropy to promote maladaptation and disease. While cardiomyopathies have classically been attributed to primary cellular defects, emerging evidence suggests that abnormal regional stress may act as a primary driver of pathology even in the absence of intrinsic sarcomeric dysfunction. This review proposes the concept of ‘cardiac mechanopathies’, conditions in which misdirected or disproportionate mechanical forces are hypothesised to act as primary determinants of maladaptive remodelling, culminating in a cardiomyopathic phenotype. Clinical paradigms include arrhythmogenic mitral valve prolapse and apical hypertrophic cardiomyopathy with papillary muscle displacement. While a direct causality link still needs to be established, this concept is conceived as a working hypothesis for future studies. Advanced imaging may help identify subtle structural abnormalities early, while insights into the molecular basis of maladaptation may reveal new therapeutic targets. Clinically, studies are needed to understand whether reducing mechanical stress through interventions and lifestyle modifications can mitigate disease expression and progression.
- Open Access
- 1 April 2026
- Published by Elsevier in JACC: Heart Failure
- Vol. 14 (8) , 103048
Fetal Right Ventricular Dilatation and Dysfunction as a Precursor of Dilated Cardiomyopathy
- 1 April 2026
- Published by Elsevier in JACC: Heart Failure
- Vol. 14 (8) , 103048
Open AccessFetal Right Ventricular Dilatation and Dysfunction as a Precursor of Dilated Cardiomyopathy
- 9 March 2026
- Published by Springer Nature in The International Journal of Cardiovascular Imaging
- Vol. 42 (9) , 1-2
Foetal detection of a mitral leaflet mass
- 9 March 2026
- Published by Springer Nature in The International Journal of Cardiovascular Imaging
- Vol. 42 (9) , 1-2
Foetal detection of a mitral leaflet mass
- Open Access
- 28 January 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Quality of Care and Clinical Outcomes
- Vol. 12 (4) , 528-541
Population-based screening for conditions associated with juvenile sudden cardiac death: a systematic review and meta-analysis
Aims: Juvenile sudden cardiac death (SCD) is predominantly caused by inherited or congenital heart conditions. While structured screening programmes for competitive athletes are well established, current international guidelines emphasize a gap of evidence regarding the value of mass screening in the general youth population. This systematic review aimed to assess the effectiveness of large-scale screening programmes in detecting conditions associated with SCD among young individuals. Methods and results: We conducted a systematic review following PRISMA guidelines, with the protocol registered in PROSPERO (CRD42024540606). Original studies evaluating cardiovascular screening in young individuals were included, while studies exclusively involving competitive athletes were excluded. Nineteen studies encompassing 1 079 781 participants from multiple countries were finally analysed. Most studies (68%) were published recently and primarily targeted children and adolescents aged 6–19 years; 63% were assessed as having a low risk of bias. Screening modalities included electrocardiography (ECG) alone (26.3%), questionnaires alone (5.3%), and a combination of both (68.4%). Following second- or third-line investigations, the overall diagnostic yield for SCD-risk conditions was 1.4‰ (1.9‰ in the meta-analysis). The pooled prevalence, estimated using a random-effects model, was 2.23‰ (95% CI: 0.94–5.29‰), with extremely high heterogeneity among studies (I2 = 100%, P < 0.0001). Conclusion: Systematic cardiovascular screening may help identify young individuals at increased risk for SCD, providing a potentially meaningful diagnostic yield. However, the absence of long-term data on outcome and cost-effectiveness underscores the need for further research to refine screening protocols, assess sustainability, and inform evidence-based public health policies.
- 28 January 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Quality of Care and Clinical Outcomes
- Vol. 12 (4) , 528-541
Open AccessPopulation-based screening for conditions associated with juvenile sudden cardiac death: a systematic review and meta-analysis
Aims: Juvenile sudden cardiac death (SCD) is predominantly caused by inherited or congenital heart conditions. While structured screening programmes for competitive athletes are well established, current international guidelines emphasize a gap of evidence regarding the value of mass screening in the general youth population. This systematic review aimed to assess the effectiveness of large-scale screening programmes in detecting conditions associated with SCD among young individuals. Methods and results: We conducted a systematic review following PRISMA guidelines, with the protocol registered in PROSPERO (CRD42024540606). Original studies evaluating cardiovascular screening in young individuals were included, while studies exclusively involving competitive athletes were excluded. Nineteen studies encompassing 1 079 781 participants from multiple countries were finally analysed. Most studies (68%) were published recently and primarily targeted children and adolescents aged 6–19 years; 63% were assessed as having a low risk of bias. Screening modalities included electrocardiography (ECG) alone (26.3%), questionnaires alone (5.3%), and a combination of both (68.4%). Following second- or third-line investigations, the overall diagnostic yield for SCD-risk conditions was 1.4‰ (1.9‰ in the meta-analysis). The pooled prevalence, estimated using a random-effects model, was 2.23‰ (95% CI: 0.94–5.29‰), with extremely high heterogeneity among studies (I2 = 100%, P < 0.0001). Conclusion: Systematic cardiovascular screening may help identify young individuals at increased risk for SCD, providing a potentially meaningful diagnostic yield. However, the absence of long-term data on outcome and cost-effectiveness underscores the need for further research to refine screening protocols, assess sustainability, and inform evidence-based public health policies.
- Open Access
- 6 November 2025
- Published by Elsevier in International Journal of Cardiology
- Vol. 444, 133999
European task force reclassification of dilated and non-dilated cardiomyopathies identifies a high arrhythmic-risk overlap phenotype
- 6 November 2025
- Published by Elsevier in International Journal of Cardiology
- Vol. 444, 133999
Open AccessEuropean task force reclassification of dilated and non-dilated cardiomyopathies identifies a high arrhythmic-risk overlap phenotype
- Open Access
- 30 October 2025
- Published by Elsevier in JACC: Case Reports
- Vol. 30 (40) , 105852
From Fetal Diagnosis to Staged Percutaneous Palliation
- 30 October 2025
- Published by Elsevier in JACC: Case Reports
- Vol. 30 (40) , 105852
Open AccessFrom Fetal Diagnosis to Staged Percutaneous Palliation
- Open Access
- 25 April 2025
- Published by Elsevier in JACC: Advances
- Vol. 4 (5) , 101730
Genotype-Negative Patients With Familial Hypertrophic Cardiomyopathy
- 25 April 2025
- Published by Elsevier in JACC: Advances
- Vol. 4 (5) , 101730
Open AccessGenotype-Negative Patients With Familial Hypertrophic Cardiomyopathy
- Open Access
- 17 February 2025
- Published by MDPI AG in Diagnostics
- Vol. 15 (4) , 481
Congenital Heart Disease After Mid-Age: From the “Grown-Up” to the Elderly
Early surgery and improved medical care have led to the increased survival of neonates with congenital heart disease (CHD), who now commonly reach adulthood. Among adults with CHD, a growing subgroup is represented by middle-aged and even elderly patients. In this elderly population, acquired cardiac and extracardiac comorbidities represent the main cause of morbidity and mortality; the control and correction of cardiovascular risk factors or an appropriate check for extracardiac complications (such as malignancies) is therefore of paramount importance. Complications and frailty syndrome appear to occur earlier in ACHD than in the general population due to a frequent discrepancy between chronological and biological age. Multiple stressors throughout life (hemodynamic abnormalities, cardiac operations and interventional procedures, the placement of foreign materials) that result in a chronic inflammatory response are among the leading causes of premature senescence. This review is aimed at assessing the characteristics and special needs of this elderly ACHD population with a view to proposing novel models for the organization of extended care.
- 17 February 2025
- Published by MDPI AG in Diagnostics
- Vol. 15 (4) , 481
Open AccessCongenital Heart Disease After Mid-Age: From the “Grown-Up” to the Elderly
Early surgery and improved medical care have led to the increased survival of neonates with congenital heart disease (CHD), who now commonly reach adulthood. Among adults with CHD, a growing subgroup is represented by middle-aged and even elderly patients. In this elderly population, acquired cardiac and extracardiac comorbidities represent the main cause of morbidity and mortality; the control and correction of cardiovascular risk factors or an appropriate check for extracardiac complications (such as malignancies) is therefore of paramount importance. Complications and frailty syndrome appear to occur earlier in ACHD than in the general population due to a frequent discrepancy between chronological and biological age. Multiple stressors throughout life (hemodynamic abnormalities, cardiac operations and interventional procedures, the placement of foreign materials) that result in a chronic inflammatory response are among the leading causes of premature senescence. This review is aimed at assessing the characteristics and special needs of this elderly ACHD population with a view to proposing novel models for the organization of extended care.